CDK2 also was a biomarker for other cancers and next-generation CDK2 inhibitors play an increasingly pivotal role in the treatment of cancer (Wadler, 2001; Chohan et al., 2015; Tadesse et al., 2020). The gene discussed is CDK2; the disease is cancer.